# A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

> **NCT04476849** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Healthy Volunteers
- Renal Impairment

## Interventions

- **DRUG:** fezolinetant

## Key facts

- **NCT ID:** NCT04476849
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2022-03-06
- **Final completion:** 2022-03-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476849, "A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04476849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*